Cerus Corp CFO green sells $211k in shares

Cerus reported Q4 2025 revenue of $233.8M (+16% YoY) with EPS of -$0.01, meeting expectations. CFO Kevin Dennis Green sold 127,544 shares on Mar 12, 2026 for $211,365 at $1.62–$1.73 to cover tax/brokerage on RSU vesting; he now holds 1,040,551 shares. Shares trade at $1.80 (market cap $347.83M) and are down ~6.74% over the past week; Vivek Jayaraman will become CEO on July 1, 2026 with current CEO William Obi Greenman moving to executive chairman.

Analysis

Cerus sits at an inflection where commercial execution and procurement timing matter more than headline quarterly moves. Hospitals and blood centers buy on budget cycles and multi-quarter evaluation windows, so revenue inflection is likely lumpy — expect material customer announcements and volume step-ups to show up over 3–12 month horizons rather than in the next earnings beat. Suppliers of single-use disposables and contract manufacturers tied to pathogen-reduction kits are second-order beneficiaries if adoption accelerates; conversely, legacy sterilization/irradiation equipment vendors face gradual demand erosion as replacement cycles kick in over several years.

Near-term price action will be driven by technical supply: RSU vesting and tax-driven selling can create transient supply pressure for days-to-weeks, but this is not informative on medium-term adoption or regulatory pathways. Real tail risks are event-driven — an adverse real-world safety signal or a negative reimbursement ruling could compress multiples quickly; conversely, a large hospital network contract or favorable payer guidance would validate steep upside. Monitor regulatory guidance, major network contracts, and manufacturing throughput metrics as primary catalysts over the next 6–18 months.

The market appears to underweight execution risk tied to the management change while simultaneously over-penalizing the stock for vesting-related share sales; that creates a window to position asymmetrically around binary commercial catalysts. Risk management should focus on protecting against headline volatility (30–60 day windows) while allowing 9–18 months for adoption and margin recovery to re-rate the company. If adoption proves sticky, expect the valuation gap versus larger blood-tech peers to compress materially as recurring disposable kit revenue scales.

Key Decisions for Investors

• Buy CERS equity on an 8–12% pullback within the next 2–6 weeks; horizon 6–12 months. Risk: set a 30% stop loss from entry; Reward: asymmetric upside if 1–2 large hospital contracts or improved utilization are announced (target 60–100% upside vs downside limited by stop).
• Trade a limited-risk options spread: buy 18–24 month CERS LEAP call and sell a higher strike to fund premium (call-call spread). Entry: within 3 months; sizing: 2–4% of strategy NAV. Risk/Reward: capped downside to premium paid, with 2–4x potential if adoption accelerates and sentiment normalizes over 12–24 months.
• Pair trade (idiosyncratic): long CERS / short GRFS (Grifols) sized to neutralize overall blood-industry beta, 12-month horizon. Rationale: capture re-rating from company-specific adoption while hedging broad sector moves. Risk: sector-specific shocks; use 15–20% notional sizing and re-evaluate after each major contract/regulatory update.
• Capital-protected entry for risk-averse: buy CERS shares and purchase a 3-month protective put covering ~50% of position size around the leadership transition window. Timeframe: tactical protection for 60–90 days, then reassess based on initial post-transition commercial disclosure.